7:35am | Registration and Coffee

8:05 am Chair’s Opening Remarks

8:15 am Development & Functional Characterisation of Chimeric Engulfment Receptor (CER) T-Cells for the Treatment of Hematologic & Solid Malignancies

  • John Rossi Senior Vice President, Translational Medicines & Research, CERo Therapeutics


  • New drug targets and next generation engineered T-cell products are needed to overcome current limitations of scFv- based CARs
  • Novel CER-T cell products leveraging naturally occurring phagocytic receptors represent a new class of cell therapy products targeting tumour stress ligands
  • Engulfment and enhanced APC-like function of CER-based products are hypothesised to overcome heterogeneous disease through recruitment of endogenous adaptive and innate anti-tumour immune response

8:45 am Allogeneic Multi-Tumour-Associated Antigen-Specific T-Cell Therapy

9:15 am How to Overcome Apheresis Products Variability in Cell and Gene Therapy Manufacturing: Best Practices in Optimizing Cell Collection

  • Simone Steiner Head, Technical Development and Manufacturing, Tigen Pharma
  • Sara Lewandowski Data Services Manager, Terumo Blood and Cell Technologies


In this plenary session:

  • Simone Steiner (Head-Technical Development and Manufacturing at Tigen Paharma) will explain how she sees apheresis as being an integral part of the production process and
    challenges around it
  • Sara Lewandowski (Data Services Manager at Terumo Blood and Cell Technologies) will share her expertise on cell collection optimization services

9:45am | Morning Refreshments

10:15am | Structured Networking


Approaches to Optimise Tumour Responses to Cell Therapies

10:45 am TCR-NK: A Novel Treatment Paradigm For The Treatment of Solid Cancer

  • Namir Hassan Chief Executive Officer , Zelluna Immunotherapy


  • TCR-NK is a novel treatment paradigm that brings together the well validated solid tumour targeting mechanism of T-Cell Receptors (TCRs) with the pan cancer recognition and highly potent activity of Natural Killer Cells (NKs)
  • We show the polyfunctionality of TCR-NKs triggered by both the high specificity of TCRs as well as pan cancer innate NK recognition resulting in activity against various cancers with the potential to overcome tumour heterogeneity
  • We are developing a platform to deliver a pipeline of novel TCR-NK therapies for the treatment of solid cancers

11:15 am Writing the Future of Cell Therapies using the Twist Biopharma Library of Libraries


  • Utilising its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody and TCR discovery libraries including both
    (1) highly diverse synthetic naïve scFv and VHH antibody phage display libraries to discover targeting domains for CAR-T constructs, and
    (2) combinatorically assembled TCR libraries from gene fragments
  • In this talk, Aaron Sato, CSO, will present several POC data on how these technologies can be utilised for cell therapies

11:45 am Harnessing Natural gd T-cell Receptors (gd TCR) to Develop Effective Cellular Therapies for Solid Tumors


• Understanding the unique cancer targeting properties of γδ TCRs
• Advantages of using engineered αβT cells engineered to express a defined tumor-reactive natural γδ TCR (TEG)
• Broadly applicability of γδ TCRs for building allogeneic T cell platforms that retain native recognition and signaling properties

12:15 pm Track Closed

Advancing Clinical Development

Enhancing Clinical Performance of CARS for Greater Persistency & Durability

10:45 am Maintaining Both Innate Killing & Specific Targeting of Heterogeneous Tumours with Chemotherapy-Resistant Chlorotoxin CAR-T Cells


  • Tumour heterogeneity can be addressed by upregulating broadly-expressed stress-induced surface antigens with chemotherapy and targeting these antigens with chemotherapy-resistant cells
  • We will discuss the use of Chlorotoxin to improve delivery of CAR-T cells to the tumour site while maintaining their multiple tumour cytolytic functions.
  • Supercharging optimisation and translation of allogeneic products

11:15 am A Landscape Overview of CAR-T Cell Therapy


  • A look at the current trends in clinical landscape
  • The current landscape of the cell therapies themselves
  • A look to the future of cell therapies

11:45 am ARC-sparX : A Modular & Universal Cell Platform


  • An overview of the ARC-sparX platform and how it may be used to address some of the limitations of standard CAR-T cells therapies
  • Modular approach allows for multiple tumour antigen targeting with a universal cell product
  • Control of effector cell and antigen interaction has potential to control expansion kinetics and therefore toxicity profile
  • Combined, this approach may reduce exhaustion, improve efficacy against heterogeneous tumours, and minimise toxicity related to uncontrolled cell expansion

12:15 pm Track Closed


Leveraging Novel Technologies to Scale & Enhance the Production of Next Generation CAR-T Cells

10:45 am Smart Manufacturing Technologies for Cell & Gene Therapy Products


  • Challenges in the manufacturing of viral vectors and CAR-T cell products
  • Challenges in the analytics of vectors and CAR-T cell products
  • Current and upcoming technologies to address the challenges








11:15 am Standardizing in-process QC with the Accellix Automated Flow Cytometry Platform.

  • Amanda Trent PhD, Director of Assay Development , Accellix


  • The Accellix platform provides automated sample preparation, data acquisition, and cell phenotyping analysis in 30 minutes with minimal operator training or input
  • Standard and custom assay kits combined with autoclassification algorithms tailored for each drug product allow for real-time testing and reproducible results at each stage of cell therapy manufacturing
  • Precision and accuracy data will be presented, along with an overview of the custom assay development process

11:45 am Developing Next-Generation TCR-T Therapies by CD8 Co-Expression


  • Outlining next-gen approaches for TCR-engineered T-cell therapies for solid tumors
  • Enhancement of anti-tumor immune responses through effective engagement of CD4 T cells
  • Exploring the differential functional profiles of TCR-T cells co-expressing different types of CD8 co-receptors






12:15 pm Advances in Lentiviral Technology and Manufacturing Processes


  • Novel lentiviral genomes and associated technology to improve productivity, quality, and enhanced safety
  • Generation of stable, inducible, lentiviral vector producer cell lines (PCL’s) for CAR therapy
  • Development of an improved production process to increase yield, reduce residual contaminants and improve quality

12:45 pm Lunchtime Refreshments

Enhancing T-Cell Function & Persistence with Novel Gene Engineering

1:45 pm BOXR: A Platform for Improving T-Cell Performance in the Solid Tumour Microenvironment


  • BOXR Bolt-On CHImeric Receptor is a platform to identify novel transgenes that can enhance CAR-T performance in the solid tumour microenvironment
  • BOXR1030 is SOTIO’s first clinical candidate. It is a GPC3-targeted CAR-T enhanced with the mitochondrial enzyme GOT2 which enhances T-cell performance in low glucose and low oxygen in vitro models and stringent xenograft models





2:15 pm Metabolic Fitness in CAR-T Cells Traversing Harsh Environments

  • Roddy O’Connor Research Assistant Professor, Center for Cellular Immunotherapies, UPenn School of Medicine


  • Discuss how intrinsic metabolic features such as spare respiratory capacity and ATP replenishment support T-cell function
  • Describe engineering approaches to arm CAR-T cells with metabolic genes to leverage environmental conditions in their favour






2:45 pm Multiplex Gene Engineering with miCAR – Moving Beyond Editing to Create Next Generation Allogeneic Cell Therapies

  • Sven Killi Chief Executive Officer, Antion Biosciences SA


  • Understanding the potential of miCAR engineering in creating Multiplex engineered all cell therapies
  • Why choose miCAR over gene editing
  • Showcasing relevant preclinical data

Advancing “Off-the-Shelf” Clinical Development for Optimal Patient Outcomes

1:45 pm Making Solid Tumour Immunotherapy Safer and More Accessible

  • Brian Philip Associate Director of Allogeneic Therapy, Triumvira Immunologics Inc


  • TAC T-cell Antigen Coupler technology works directly with the T cell receptor to aid tumour recognition and targeting
  • Closely mirroring the natural T cell response TAC technology offers key advantages including reduced risk of tonic signalling, reduced risk from cytokine release, and retention of memory phenotype on engineered cells
  • TAC design offers potential for both autologous and allogeneic application

2:15 pm Leveraging Clinical and Translational Insights from Next Generation SPEAR T-cells: Building a MAGE A4 T-Cell Therapy Franchise

2:45 pm A Phase 1/2 Dose-Escalation & Dose-Expansion Study of the Safety & Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / Acute Lymphoblastic Lymphoma (LBL)


  • Introducing WU-CART-007 an allogeneic, fratricide resistant CAR-T cells for the treatment of CD7 hematological malignancies
  • Discuss clinical development plans and trial update

Exploring the CAR-X Landscape: Using iPSCs and NK Cells to Drive Allogeneic Solid Tumor Treatment

1:45 pm Exploring the Potential of Combining Engineered iPSC NK Cells with NK cell Engagers and the Future of Cell Therapies


• Advantages of IPSC derived NK products vs NK cell line, donor derived, or cord blood
• Advantages of NK cell therapies over CAR-T cell therapies
• Advantages of TALEN over CRISPR

2:15 pm Induced Pluripotent Stem Cell-Derived Natural Killer Cells for the Treatment of Solid Tumours

  • Rudy Gonzalez Executive Director of Stem Cell Therapeutics, Caribou Biosciences


• Next-generation genome editing of induced pluripotent stem cells
• Differentiation and expansion of induced pluripotent stem cells into NK cells (iNK)
• iNK characterisation and proof of concept preclinical studies in solid tumour models

2:45 pm Driving Ex Vivo Expansion of Allogeneic CAR Cells Through Rapamycin-Activated Cytokine Signalling


  • The Rapamycin Activated Cytokine Receptor (RACR) platform can be leveraged for cell therapy both in vivo and ex vivo
  • In vivo the RACR provides controlled proliferation via rapamycin-mediated IL-2/IL-15 cytokine signalling and protection of RACR-expressing cells from the host immune system by rapamycin tolerisation
  • Ex vivo the RACR can be leveraged to expand cells independent of endogenous cytokine receptor expression



3:15 pm Afternoon Break

Supercharging Novel Target Discovery to Reach Wider Patient Populations

3:45 pm Supercharging Development of Innovative Platforms for Identification and Validation of Novel Targets Beyond CD19

  • Marvin Gee VP of Target Discovery, Co-Founder, 3T Biosciences


• Identifying novel targets with potential to develop next generation CAR-TCR therapies with reduced toxic effects of on-target-off-tumour reactivity
• Innovative preclinical and clinical trial designs to maximise patient success
• Exploring new ways to model tumour burden to gain a realistic representation of translation in humans
• Validating pre-clinical models and interpreting data from these models correctly

CAR-TCR Applications Beyond Oncology

3:45 pm Use of Engineered Regulatory T-Cells to Induce Immunologic Tolerance: Path to the Clinic


• Rational and preliminary data to support the use of antigen-specific Tregs as a therapeutic approach
• Engineering technologies to improve Treg efficacy in the clinical application

4:15 pm Engineering TCR & CAR-T Cells Through Hematopoietic Stem Cells

  • Scott Kitchen Director & Associate Professor – Medicine, UCLA


• Engineering blood forming (hematopoietic) progenitors with TCRs or CARs to target chronic viral infection or malignancies to create an infinite source of T-cells
• Demonstrating long-term benefit and T-cell persistence in humanised mice and nonhuman primate models
• Demonstration of safety and efficacy and the next steps in clinical translation

Exploring the CAR-X Landscape: Using iPSCs and NK Cells to Drive Allogeneic Solid Tumor Treatment

3:45 pm Allogenic Solid Tumor Immunotherapy using iPSCDerived Gene-Edited iNK Cells

4:15 pm Memory-Like NK Cell CARs for Mesothelin Expressing Solid Tumours

  • Mubin Tarannum Post-Doctoral Researcher, Dana-Farber Cancer Institute


• Mesothelin is as an attractive target in multiple solid tumours
• Lab efforts towards using memory-like NK cells for CAR editing
• Preclinical data demonstrating activity of memory-like NK cell CARs against mesothelin expressing solid tumour cell lines and patient derived organoid tumours (PDOTs)

Meeting Wider Patient Populations with Improved Safety & Delivery

4:45 pm Novel Gamma-Delta CAR-T approaches for systemic delivery in Solid Tumors

5:00 pm Towards Next Generation CAR Therapy Including In Vivo Programming of Immune Cells & Non-Oncology Indications

  • Adrian Bot, MD, PhD Chief Scientific Officer and Executive Vice President, R&D, Capstan Therapeutics


  • Development of first wave ex vivo manufactured autologous CAR-T cell products for B-cell malignancies yielded invaluable lessons, paving the way to next generation therapies
  • Key opportunities to expand the footprint of this treatment modality include design and development of transformative off-the-shelf therapies including in vivo CARs, as well as translation of this technology to non-oncology indications – both explored in this presentation

5:30 pm Chair’s Closing Remarks

5:45 pm End of Summit